LIXTE’s LB-100 Targets Precision Oncology: Enhancing Chemo & Reducing Side Effects
April 24, 2026 — LIXTE Biotechnology Holdings (LIXT) advances precision oncology with LB-100, a PP2A inhibitor enhancing chemo/radiation. Learn about its novel activation lethality approach and clinical trials. Read more.